Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 2, 2010, Pages 305-310

  Zuo, Zhong ^a   Wo, Siu Kwan ^a   Lo, Cindy M Y ^a   Zhou, Limin ^a   Cheng, Gregory ^a   You, Joyce H S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

LC MS MS; R 7 Hydroxywarfarin; R Warfarin; S 7 Hydroxywarfarin; S Warfarin

Indexed keywords

7 HYDROXYWARFARIN; UNCLASSIFIED DRUG; WARFARIN;

ACCURACY; ARTICLE; BLOOD SAMPLING; CATION EXCHANGE; CHIRALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG METABOLISM; ENANTIOMER; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STEADY STATE; TANDEM MASS SPECTROMETRY;

ANTICOAGULANTS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FREEZING; HUMANS; MOLECULAR STRUCTURE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TEMPERATURE; TIME FACTORS; WARFARIN;

EID: 77349092774     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.01.005     Document Type: Article

References (19)

1. Kaminsky L., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 1997, 73:67-74.
2. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Effy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., Trager W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 1992, 5:54-59.
3. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 2002, 72:702-710.
4. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., Roitelman J., Harats D., Halkin H., Ezra D. Interindividual variability in sensitivity to warfarin-nature or nurture? Clin. Pharmacol. Ther. 2001, 70:159-164.
5. O'Sullivan T.A., Wang J.P., Unadkat J.D., al-Habet S.M., Trager W.F., Smith A.L., McNamara S., Aitken M.L. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin. Pharmacol. Ther. 1993, 54:323-328.
6. Linder M.W., Looney S., Adams J.E., Johnson N., Antonio-Green D., Lacefield N., Buckaveckas B.L., Valdes R. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis 2002, 14:227-232.
7. Henne K.R., Gaedigk A., Gupta F., Leeder J.S., Rettie A.E. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype. J. Chromatogr. B 1998, 710:143-148.
8. Osman A., Arbring K., Lindahl T.L. A new high-performance liquid chromatographic method for determination of warfarin enantiomers. J. Chromatogr. B 2005, 826:75-80.
9. Ring P.R., Bostick J.M. Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection. J. Pharm. Biomed. Anal. 2000, 22:573-581.
10. Locatelli I., Kmetec V., Mrhar A., Grabnar I. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J. Chromatogr. B 2005, 818:191-198.
11. Takahashi H., Kashima T., Kimura S., Muramoto N., Nakahata H., Kubo S., Shimoyama Y., Kajiwara M., Echizen H. Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J. Chromatogr. B 1997, 701:71-80.
12. Zhou Q., Yau W.P., Chan E. Enantioseparation of warfarin and its metabolites by capillary zone electrophoresis. Electrophoresis 2003, 24:2617-2626.
13. Uno T., Niioka T., Hayakari M., Sugawara K., Tateishi T. Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation. Ther. Drug Monit. 2007, 29:333-339.
14. Kollroser M., Schober C. Determination of coumarin-type anticoagulants in human plasma by HPLC-electrospray ionization tandem mass spectrometry with an ion trap detector. Clin. Chem. 2002, 48:84-91.
15. Ufer M., Kammerer B., Kirchheiner J., Rane A., Svensson J. Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. J. Chromatogr. B. 2004, 809:217-226.
16. Zhang Z.Y., King B.M., Wong N. Quantitative liquid chromatography/mass spectrometry/mass spectrometry warfarin assay for in vitro cytochrome P450 studies. Anal. Biochem. 2001, 298:40-49.
17. Naidong W., Ring P.R., Midtlien C., Jiang X. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J. Pharm. Biomed. Anal. 2001, 25:219-226.
18. Lawrence R.F., Rettie A.E., Effy A.C., Trager W.F. Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations. Chirality 1990, 2:96-105.
19. Mcaleer S.D., Foondun A.S., Feely M., Chrystyn H. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients. Chirality 1997, 9:13-16.